Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
To demonstrate the superiority of paricalcitol treatment at early renal post-transplantation
(M6) in the control of iPTH (Intact parathyroid hormone) compared to the use of vitamin D
nutritional supplements (calcifediol) in patients with renal transplantation.
Phase:
Phase 4
Details
Lead Sponsor:
Fundación Senefro
Collaborators:
AbbVie Effice Servicios Para la Investigacion S.L.